Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quercetin - Quercegen Pharmaceuticals

Drug Profile

Quercetin - Quercegen Pharmaceuticals

Alternative Names: Q Force; QU995™

Latest Information Update: 18 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Chemical Reagent Factory; Catholic University of the Sacred Heart - Rome; Farr Laboratories LLC; Indiana University School of Medicine; Quercegen Pharmaceuticals; Singapore General Hospital; SRI International; Taiyuan Pharmaceutical Factory; University of Birmingham; University of California at Los Angeles; University of Ulster
  • Developer National Institutes of Health (USA); Quercegen Pharmaceuticals; University of Michigan
  • Class Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Enzyme inhibitors; Free radical scavengers; Platelet aggregation inhibitors; Prostaglandin synthase stimulants; Protein tyrosine kinase inhibitors; Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic obstructive pulmonary disease
  • Discontinued Atherosclerosis; Cancer; Cardiovascular disorders; Prostatitis

Most Recent Events

  • 13 May 2022 Pharmacodynamics data from a preclinical trial presented at the 118th International Conference of the American Thoracic Society (ATS-2022)
  • 08 Dec 2016 M. D. Anderson Cancer Center plans a phase 0 trial for Chemotherapy induced neuropathic pain in USA (NCT02989129)
  • 13 Feb 2014 Phase-I/II clinical trials in Chronic obstructive pulmonary disease in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top